Prolonged Infusion of Low Dose Gemcitabine in Advanced Pancreatic Carcinoma  

作　　者：Elsayed Mostafa Ali Ahmed M. Maklad Salah M. Khallaf Elsayed Mostafa Ali;Ahmed M. Maklad;Salah M. Khallaf(Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Sohag, Egypt;Medical Oncology Department, South Egypt Cancer Institute, Assiut, Egypt)

机构地区：[1]Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Sohag, Egypt [2]Medical Oncology Department, South Egypt Cancer Institute, Assiut, Egypt

出　　处：《Journal of Cancer Therapy》2020年第7期401-409,共9页癌症治疗（英文）

摘　　要：<strong>Background:</strong> <span><span><span style="font-family:""><span style="font-family:Verdana;">Gemcitabine was established as a monotherapy or in combination for locally advanced or metastatic pancreatic carcinoma. </span><b><span style="font-family:Verdana;">Aim:</span></b><span style="font-family:Verdana;"> This study aimed to evaluate the efficacy of the low-dose gemcitabine over 6-hour infusion in patients with advanced pancreatic adenocarcinoma. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">26 patients with locally advanced or metastatic pancreatic carcinoma were recruited into the study from December 2013 to October 2014. Patients received the treatment in Clinical Oncology Department, Sohag University, and Medical Oncology Department, Assiut University. Patients received low-dose gemcitabine (250 mg/m</span>^{<span style="font-family:Verdana;">2</span>}<span style="font-family:Verdana;">) over 6-hour infusion, weekly for seven weeks and then on days 1 and 8 every 3 weeks till unacceptable toxicity or progression of the disease. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">Twenty-six patients were enrolled in this study. After starting 7 weeks of treatment, the disease control rate was 38.5% in the form of complete response in 3.8% of patients, partial response in 26.9%, and sta</span><span style="font-family:Verdana;">tionary response in 7.7%. However, disease progression occurred in 61.5%. Progression-free survival</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">s</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">were</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> 65.38%, 23.07%, 7.69% a<strong>Background:</strong> <span><span><span style="font-family:""><span style="font-family:Verdana;">Gemcitabine was established as a monotherapy or in combination for locally advanced or metastatic pancreatic carcinoma. </span><b><span style="font-family:Verdana;">Aim:</span></b><span style="font-family:Verdana;"> This study aimed to evaluate the efficacy of the low-dose gemcitabine over 6-hour infusion in patients with advanced pancreatic adenocarcinoma. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">26 patients with locally advanced or metastatic pancreatic carcinoma were recruited into the study from December 2013 to October 2014. Patients received the treatment in Clinical Oncology Department, Sohag University, and Medical Oncology Department, Assiut University. Patients received low-dose gemcitabine (250 mg/m</span>^{<span style="font-family:Verdana;">2</span>}<span style="font-family:Verdana;">) over 6-hour infusion, weekly for seven weeks and then on days 1 and 8 every 3 weeks till unacceptable toxicity or progression of the disease. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">Twenty-six patients were enrolled in this study. After starting 7 weeks of treatment, the disease control rate was 38.5% in the form of complete response in 3.8% of patients, partial response in 26.9%, and sta</span><span style="font-family:Verdana;">tionary response in 7.7%. However, disease progression occurred in 61.5%. Progression-free survival</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">s</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">were</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> 65.38%, 23.07%, 7.69% a

关 键 词：GEMCITABINE Pancreatic Cancer Intravenous Infusion LOW-DOSE 

分 类 号：R73[医药卫生—肿瘤]